Citius Oncology (CTOR) Change in Receivables (2025 - 2026)
Citius Oncology's (CTOR) quarterly Change in Receivables came in at -$3.0 million in Q1 2026, down 173.35% on a QoQ basis from $4.0 million in Q4 2025.
Citius Oncology (CTOR) Change in Receivables (2025 - 2026) Analysis & Trends
Citius Oncology (CTOR) has 2 years of Change in Receivables data on file, last reported at -$3.0 million in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | -78.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 106.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -621.82 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -38.20 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 126.30 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 81.40 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Citius Oncology | 58.02 Mn | 58.02 Mn | 1.34 Mn | -2.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.97 Mn |
| Mar 31, 2026 | -2.97 Mn |
| Dec 31, 2025 | 4.05 Mn |
| Dec 31, 2025 | 4.05 Mn |